Compare DexCom, Inc. (DXCM) vs JetBlue Airways Corporation (JBLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs JetBlue Airways Corporation — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.86B), while JetBlue Airways Corporation trades at $3.9 (market cap $1.48B). The key difference: DexCom, Inc. is far larger — about 21.5× JetBlue Airways Corporation's market cap, and DexCom, Inc. is trading nearer its 52-week high, JetBlue Airways Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and JetBlue Airways Corporation for 44 Days on average.
| DXCM | JBLU | |
|---|---|---|
Market Cap | $31.86B | $1.48B |
Volume | 3,607,070 | 30,275,693 |
Sector | Health | Industrials |
52-Week High | $92.34 | $6.46 |
52-Week Low | $54.84 | $3.92 |
Typical Hold Time | 62 Days | 44 Days |
Enterprise Value | $31.32B | $8.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
JetBlue (JBLU) trades at $3.97, down 1.49% today, with a bearish technical outlook despite oversold RSI levels. The airline faces fundamental challenges with consecutive quarterly losses, negative profit margins (-9.32%), and elevated debt levels (debt-to-asset ratio of 51.28% in 2025). Recent developments include route expansion to Colombia and the launch of premium BlueFirst seating, but operational cash flow remains negative (-$94M in 2025).
The investment outlook is cautious given persistent losses and high leverage, though the current valuation (P/S 0.15, P/B 0.93) appears discounted. Analyst consensus is mixed with a $5.89 price target (48% upside) but predominantly Hold ratings (62%). Key risks include fuel cost volatility, competitive pressure, and macroeconomic sensitivity to travel demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →
